Little Health Law Blog

Our healthcare law firm works with many providers and healthcare practices to assist them in complying with federal, state, and local laws. This blog post discuses which licensed professionals can draw blood in Georgia depending on the particular circumstance and the professional’s particular license. If you are planning to draw blood as part of your scope of practice, respond to a licensing dispute about drawing blood, or would like to discuss this blog post, you may contact our healthcare law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.

Georgia law and regulations do not have clear rules on who can or cannot draw blood. Regarding blood donation centers, for example, phlebotomists must have the Continue reading ›

Our healthcare law firm works with many providers and healthcare practices to assist them in complying with federal, state, and local laws. Our med spa clients in South Carolina ask what services they can legally provide at their med spa, especially Botox. This blog post discuses who can administer Botox in South Carolina. If you are planning to start a med spa in South Carolina, administer Botox in your practice, or would like to discuss this blog post, you may contact our healthcare law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.

Who Can Administer Botox Depends on Whether Botox Is Being Administered for Cosmetic or Non-Cosmetic Purposes.

The South Carolina State Boards of Dentistry, Medical Examiners, and Nursing issued a joint advisory opinion about administering neuromodulators, including Botox, for cosmetic and non-cosmetic purposes. The opinion discusses certain requirements to administer Botox. A practitioner must Continue reading ›

Our healthcare and business law firm advises many physicians and medical practices on Medicare compliance, including one of the most foundational questions a Medicare-participating provider must answer before offering a new service: is this a covered service? The answer has significant legal and financial consequences. This post walks through a framework for analyzing whether a service is covered under Medicare, why that distinction matters, and what options a provider has when a service may or may not be covered. If you would like to discuss Medicare compliance for your practice or would like to discuss this blog post, you may contact our healthcare and business law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.

(1) Why the Covered vs. Non-Covered Distinction Matters

As a Medicare-participating provider, you have agreed—through your provider agreement—to accept Medicare’s approved payment amount as payment in full for covered services. That means if a service is covered by Medicare, you generally cannot bill the patient a separate or higher fee for that same service. Doing so can result in severe penalties, including civil monetary penalties and exclusion from the Medicare program.

On the other hand, if a service is never a covered service, you are not bound by Medicare’s billing rates, are not required to submit a claim to Medicare, and can Continue reading ›

Our healthcare and business law firm advises many medical practices, telehealth companies, and providers on compliantly offering weight management services, including GLP-1 medications. On February 20, 2026, the Food and Drug Administration (“FDA”) issued warning letters to numerous companies offering compounded GLP-1 medications—specifically compounded semaglutide and tirzepatide. This post summarizes the FDA’s warning letter actions and outlines the top concerns the FDA has identified regarding how companies are marketing and labeling compounded GLP-1 products. If you would like to discuss GLP-1 compliance matters or would like to discuss this blog post, you may contact our healthcare and business law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.

(1) Background: FDA Warning Letters on Compounded GLP-1s

GLP-1 medications such as semaglutide (the active ingredient in Ozempic® and Wegovy®) and tirzepatide (the active ingredient in Mounjaro® and Zepbound®) have become among the most prescribed drugs in the United States. Given high demand and prior drug shortages, a large market for compounded versions of these drugs developed. As the FDA resolved shortage designations for these drugs, it began more actively scrutinizing how compounders and telehealth platforms were marketing their compounded GLP-1 products.

On February 20, 2026, the FDA’s Center for Drug Evaluation and Research (CDER) issued a wave of warning letters to companies offering compounded semaglutide and tirzepatide products. Three of those letters—sent to Continue reading ›

Our healthcare law firm works with many providers and healthcare practices to assist them in complying with federal, state, and local laws. Several of our clients have asked if they can administer ketamine for off-label use, especially for treatment-resistant depression. Ketamine has started being administered in psychiatric practices and ketamine clinics, and states are starting to respond to the proliferation of these ketamine clinics. This blog post discusses a bill in the Georgia General Assembly that proposes to regulate ketamine clinics. As of March 30, 2026, the bill has passed both the Georgia House and Senate but has not yet become law. If you are planning to administer ketamine in your practice, would like to set up a ketamine clinic, or would like to discuss this blog post, you may contact our healthcare law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.

House Bill 717 (HB 717) proposes to regulate facilities that administer “psychedelic-assisted treatment and therapy,” which includes ketamine that is administered intravenously. “Psychedelic-assisted treatment and therapy” is defined as any treatment or therapy using psychedelic, dissociative, or other related substances that can produce hallucinations or other similar feelings. This bill also covers other treatments similar to ketamine, including Spravato®. The Georgia Medical Board would also be required to Continue reading ›